PRNewsWire - Health

Kexing Biopharm's GB18 project received clearance of IND application from NMPA and FDA
Halia Therapeutics CEO Dr. David Bearss to Deliver Keynote Address at Med Investment Forum 2025 in Abu Dhabi
Innovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate Response to Anti-IL-17 Antibodies
AsyncHealth launches Crowdfunding Campaign on StartEngine using Artificial Intelligence to Revolutionize Mental Health Care